{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage+2&page=7", "query": { "condition": "Ovarian Cancer Stage 2", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 495, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage+2&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer+Stage+2&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T14:50:02.995Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00325351", "title": "ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Sagopilone (ZK 219477) + carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2006-08-24", "completion_date": "2009-03-25", "has_results": false, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 14, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325351" }, { "nct_id": "NCT00814086", "title": "Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chemotherapeutic Agent Toxicity", "Endometrial Adenocarcinoma", "Fallopian Tube Carcinoma", "Gastrointestinal Complication", "Malignant Ovarian Mixed Epithelial Tumor", "Neurotoxicity Syndrome", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Primary Peritoneal Carcinoma", "Stage II Ovarian Cancer", "Stage III Ovarian Cancer", "Stage IV Ovarian Cancer", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 23, "start_date": "2009-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-12-31", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 7, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Camden, New Jersey + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Camden", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814086" }, { "nct_id": "NCT00028496", "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Gallbladder", "Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Rectum", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Gallbladder", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Male Breast Cancer", "Mixed Adenocarcinoma of the Stomach", "Ovarian Endometrioid Adenocarcinoma", "Paget Disease of the Breast With Intraductal Carcinoma", "Paget Disease of the Breast With Invasive Ductal Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Salivary Gland Adenocarcinoma", "Stage II Malignant Testicular Germ Cell Tumor", "Stage II Pancreatic Cancer", "Stage III Colon Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Salivary Gland Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox GM-CSF vaccine adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028496" }, { "nct_id": "NCT00853307", "title": "MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Carcinoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2009-03-23", "completion_date": "2011-01-27", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 1, "location_summary": "Berkeley Heights, New Jersey", "locations": [ { "city": "Berkeley Heights", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00853307" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT04794322", "title": "Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Neoplasms", "Ovarian Epithelial Carcinoma", "Fallopian Tube Neoplasms", "High Grade Ovarian Serous Adenocarcinoma", "Stage I Ovarian Cancer", "Stage II Ovarian Cancer", "Stage III Ovarian Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Uterine lavage, or a wash of the womb", "type": "DIAGNOSTIC_TEST" }, { "name": "Blood sample", "type": "DIAGNOSTIC_TEST" }, { "name": "Pap smear", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "FEMALE", "summary": "30 Years and older · Female only" }, "enrollment_count": 250, "start_date": "2020-04-13", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • San Francisco, California • Annapolis, Maryland + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04794322" }, { "nct_id": "NCT05512208", "title": "A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrioid Cancer", "Mucinous Ovarian Cancer", "High Grade Serous Ovarian Cancer", "Cervical Cancer", "Solid Tumor" ], "interventions": [ { "name": "Avutometinib (VS-6766) + defactinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 55, "start_date": "2023-02-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 4, "location_summary": "Orlando, Florida • New Orleans, Louisiana • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05512208" }, { "nct_id": "NCT05716295", "title": "A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "MDK-703", "type": "DRUG" }, { "name": "Checkpoint Inhibitor, Immune", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medikine, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 26, "start_date": "2023-02-08", "completion_date": "2024-04-30", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 6, "location_summary": "Sarasota, Florida • Huntersville, North Carolina • Austin, Texas + 3 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05716295" }, { "nct_id": "NCT03601897", "title": "A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "Rebastinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2018-10-25", "completion_date": "2022-05-23", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03601897" }, { "nct_id": "NCT03206047", "title": "Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Guadecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Poly ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2017-11-08", "completion_date": "2020-11-10", "has_results": false, "last_update_posted_date": "2025-03-13", "last_synced_at": "2026-10-13T14:50:02.995Z", "location_count": 17, "location_summary": "Tucson, Arizona • Duarte, California • Sacramento, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03206047" } ] }